Action Research Group Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2016
NCT02664649
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Action Research Group

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aortic Valve Stenosis (Phase 3)

Atrial Fibrillation (Phase 3)

Cardiovascular Diseases (Phase 3)

Constriction, Pathologic (Phase 3)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Hemorrhage (Phase 3)

Infarction (Phase 3)

Ischemia (Phase 3)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 3)

Thrombosis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 6